Human Kinome Screen IDs Protein Kinase as Potential Breast Cancer Drug Target
May 27, 2011
Human Kinome Screen IDs Protein Kinase as Potential Breast Cancer Drug Target
The kinase, LMTK3, regulates estrogen receptor α, which is key to patient response to endocrine therapies like tamoxifen. A study of 613 breast cancer samples linked high LMTK3 expression levels to significantly shorter disease-free survival and overall survival.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Yale Researcher Suggests More Focus on EGFR Isoforms Needed in Development of Antibody-Based Drugs
May 20, 2011 / ProteoMonitor - Hutch, Broad Teams Publish Comprehensive Methods for MS-Based Biomarker Discovery and Verification
July 29, 2011 / ProteoMonitor - Taking Aim at Clinical Oncology Market, Proteome Sciences Developing SRM-MS Assay for ER Status
July 22, 2011 / ProteoMonitor - Evotec to Use PhosphoScout Platform in Oncology Biomarker Alliance with Roche
July 1, 2011 / ProteoMonitor - Researchers ID Gastric Cancer Biomarker Aimed for Use in DTC Tests in US, China
May 6, 2011 / ProteoMonitor